No savings at 50? 2 FTSE 100 dividend stocks that could still help you retire in luxury

Are you approaching retirement with an empty wallet? Royston Wild explains how you can still get rich before the time you hang up your work apron.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pensioner poverty is something we all need to get increasingly serious about. Approximately one in 20 of retired Britons is now living close to, or beyond, the breadline. I know somebody who’s close to turning 50 with hardly any savings to fall back on.

My first piece advice to them, however, was don’t panic. It’s still possible for anyone in this position to make a sizeable nest egg in the 15-or-so years between now and the State Pension age of 65. You just need to be a bit more careful with how you use your spare cash. Time isn’t on your side, after all, so picking dependable earnings generators which offer big dividends today is essential.

Medical marvel

GlaxoSmithKline (LSE: GSK) is one Footsie share I expect to deliver exceptional shareholder returns over the next decade and a half as global demand for healthcare booms.

The patent expirations on key drugs that previously crushed earnings haven’t quite been put to bed, but investors can still look forward to solid profits growth at Glaxo as sales of its new medicines take off. During the first half, for example, the rapid growth of its recently-launched Trelegy and Nucala blockbuster brands pushed revenues at its Respiratory division 16% higher to £752m.

Its product pipeline is chock-full too, with 44 new medicines in development in fast-growing areas such as infectious diseases (including HIV), oncology and respiratory for investors to look forward to. And, judging from the steady flow of positive testing updates and regulatory approvals from across the globe, it seems as if the pharma giant’s back on the path of another golden era.

One last thing to celebrate. At current prices, Glaxo trades on a forward P/E ratio of 14.8 times and carries a big 4.6% corresponding dividend yield.

Home comforts

Another dependable, big dividend payer I reckon’s a top buy today for those approaching retirement is Taylor Wimpey (LSE: TW). It currently carries a forward P/E ratio of 7.9 times and a monster dividend yield of 11.2%, making it an irresistible buy (in my opinion at least) at today’s prices.

It’s possible the fallout of the Brexit saga could have significant negative effects for the UK economy through the next decade and thereafter, a situation that could keep property price growth hemmed in. But I’m confident the housebuilders can still thrive over the long term, given the country’s chronic homes shortage.

For decades now, government has failed to get a serious handle on the problem and there’s nothing to suggest anything is about to change. Indeed, recent Whitehall pledges to build 300,000 new homes per year by the mid-202s are already in tatters, thanks in part to the miles and miles of red tape still curtailing the creation of newbuild homes. What’s more, with ultra-low interest rates now the ‘new norm’, buyer affordability is likely to remain well-supported at least through the next decade, worsening that supply/demand imbalance still further.

Royston Wild owns shares of Taylor Wimpey. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£9,000 in savings? Here’s how to try and turn that into a £193 monthly second income

With a long-term approach and applying basic principles of good investment, our writer reckons someone with under £10k could earn…

Read more »

Investing Articles

A 2026 stock market crash could be a rare passive income opportunity

If a stock market crash comes our way then it might throw up plentiful opportunities for investors to secure a…

Read more »

Tesla car at super charger station
Investing Articles

£10,000 invested in Tesla stock 1 year ago is now worth…

Dr James Fox takes a closer look at Tesla stock with the incredibly volatile mega-cap company surging and pulling back…

Read more »

British pound data
Investing Articles

My personal warning for anyone tempted by the plunging Aston Martin share price

Harvey Jones was so captivated by the plunging Aston Martin share price that he ignored an old piece of investment…

Read more »

Stacks of coins
Investing Articles

This penny share just crashed 13% to 19p! Time to buy?

After another fall today, this penny stock has now crashed 70% since April 2021. Is it one that should be…

Read more »

Trader on video call from his home office
Investing Articles

Down 19%! Here’s why Barclays shares look a serious bargain to me right now

Barclays shares have slumped recently, but a big gap between price and fair value has opened, offering nimble long-term investors…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Why Meta Platforms shares fell 12.5% in March

Historically, investors have done well by buying Meta Platforms shares when the price has fallen. But is the latest legal…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£20,000 invested in BAE Systems shares 4 years ago is now worth…

BAE Systems' shares have soared since 2022, yet rising NATO budgets are just starting to feed through, so the real…

Read more »